National
Takano on path to make history in Calif. race
Democrat would be first out gay person of color in Congress
U.S. House candidate Mark Takano (photo courtesy Takano campaign)
Mark Takano is poised to make history.
The openly gay congressional candidate is the only Democrat running in a newly created Democratic-leaning district in California. And if he wins in November 2012, the 51-year-old Japanese-American would become the first openly gay person of color elected to Congress.
“The significance of that achievement is the unique voice that an openly gay member of Congress of color can bring to the House floor and the House committee rooms,” Takano said in an interview with the Washington Blade. “It’s a double-awareness of what it means to be vulnerable.”
Takano said this “double-awareness” comes as a result of the discrimination that both Japanese-Americans and LGBT Americans have faced in this country.
In 1942, President Franklin Roosevelt issued an executive order placing an estimated 110,000 Japanese-Americans in internment camps as the United States battled Japan during World War II. Takano said his parents and grandparents were among those who were interned, and his grandmother lost the property she owned as a result of the government’s action.
The U.S. government eventually apologized for its actions. In 1988, Congress passed and President Reagan signed legislation apologizing for the internment and disbursing more than $1.6 billion to Japanese-Americans who had been interned and their heirs. Takano said he believes the LGBT community will achieve a similar victory in reaching full legal equality.
“They were able to right the wrong by passing the Japanese-American redress bill,” Takano said. “Watching that example gives me faith that the LGBT community is also going to prevail in their quest for full inclusion and full equality. Because I’ve watched it happen.”
Takano said he expects to take the Employment Non-Discrimination Act over the finish line during his tenure in Congress. He also said he wants to work toward repeal of the Defense of Marriage Act and passage of the Uniting American Families Act.
His election to Congress would also help maintain the level of LGBT representation in the House. Rep. Barney Frank (D-Mass.), the longest-serving openly gay U.S. House member, announced in November that he won’t seek a 17th term in office. Lesbian Rep. Tammy Baldwin is leaving the House to pursue a run for U.S. Senate.
That leaves Reps. Jared Polis (D-Colo.) and David Cicilline (D-R.I.) as the only incumbent openly gay U.S. House members. Mark Pocan, another openly gay candidate, is seeking to win the seat that Baldwin is vacating.
Reflecting on Frank’s retirement, Takano said he feels a tinge of sadness that he won’t be able to serve alongside the Massachusetts Democrat.
“I really hoped as the first openly gay member of Congress who is a person of color that I get to serve with the openly gay member of Congress who’s the most colorful,” Takano joked.
He said Frank’s departure should instill a “sense of urgency” in the LGBT community in the upcoming election to maintain the number of openly LGBT people in Congress.
“If we’re going to move the agenda forward, it’s going to mean that we’re going to have to ensure that we keep the members there and increase our numbers this year,” Takano said. “We have an opportunity to do so.”
But the No. 1 priority for Takano if he’s elected to represent California’s 41st congressional district is addressing what he calls the “disastrous unemployment situation” in the country. According to the Labor Department, the national unemployment stands at 8.6 percent, which is down from recent months but still a high rate of joblessness.
Takano said that has been the top concern of the donors he’s spoken to — including LGBT donors — as he makes the case for his candidacy.
“This is a very dangerous situation for the nation to continue to have this unemployment because it threatens social stability and democratic institutions,” Takano said. “If it lasts too long, we’ll see the danger of extremist politics. I have concerns that vulnerable minorities will be in danger, so as LGBT Americans, we have a strong interest in making sure that we get all Americans back to work.”
A public school teacher for 23 years specializing in British literature, Takano also said education issues are of concern to him and he wants to reduce the high-school drop out rate while increasing the numbers of students attending college. He also said his district suffers from air pollution and he wants to be an environmental advocate in Congress.
Takano is no stranger to public service. In 1990, he was elected to the Riverside Community College District’s Board of Trustees and has served on that body since then. In 2001, Takano helped shepherd through the board a measure enabling Riverside Community College employees to have domestic partner benefits.
The candidate also made earlier attempts at winning a congressional House seat. In 1992, he defeated six contenders to win the Democratic nomination for then-California’s 43rd Congressional District. Takano didn’t succeed in the general election, but lost by fewer than 550 votes against Rep. Ken Calvert (R-Calif.) in one of the closest congressional elections in California history. Takano made another unsuccessful attempt at running for the seat in 1994.
Takano is likely to claim the Democratic nomination in the congressional race. The deadline for filing is March 9, and no other Democrat has yet to enter the race. Odds are also good for Takano in the general election. The 41st congressional district is new, but had it existed in 2008, President Obama would have won there by 20 points.
Still, even though the district is Democratic-leaning, Takano isn’t in the clear because he’ll be up against a Republican opponent. Riverside County Supervisor John Tavaglione has thrown his hat into the race.
The Human Rights Campaign, the Gay & Lesbian Victory Fund and gay Rep. Jared Polis (D-Colo.) have already endorsed Takano. During a recent trip to D.C., Takano also secured endorsements from retiring gay Rep. Frank as well as members of the House Democratic leadership, including Minority Leader Nancy Pelosi (D-Calif.) and Minority Whip Steny Hoyer (D-Md.).
Jennifer Crider, a Pelosi spokesperson, said of the Democratic leader’s endorsement of Takano, “She supports Mark Takano because he is committed to reigniting the American dream by getting people back to work, helping them stay in their homes and building strong small businesses. He will be a great representative of his district as well as the LGBT and Asian-American communities.”
Additionally, Takano also won the endorsement of fellow Japanese-American Sen. Daniel Inouye (D-Hawaii), the most senior U.S. senator. Takano said Inouye’s support is significant because the senator rarely endorses a Democratic candidate before a primary is held.
In a statement provided to the Washington Blade, Inouye said, “Mark Takano has served this newly created congressional District as a classroom teacher, college board trustee and community leader for more than two decades. As a member of the U.S. House of Representatives I am confident that Mark will work hard to create quality jobs, improve public education and preserve national security. I have known Mark for some time and I am pleased to endorse his campaign for Congress.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Using movement to boost your mental health during holidays
Reasons to be optimistic about 2026
America is going in the wrong direction for intersex children
Rush reopens after renewing suspended liquor license
Long-awaited ‘Pillion’ surpasses the sexy buzz
